Katherine Sellers, PA
Physician Assistant · Dallas, TXNPI 1699011098
Payments from drug & device makers
Across 102 payments — averaging $234.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$17K
- Sanofi-aventis U.S. LLC$2K
- Janssen Scientific Affairs, LLC$1K
- Kadmon Pharmaceuticals LLC$970
- ADC Therapeutics America, Inc.$640
- Adaptive Biotechnologies Corporation$425
- plus $2K from 20 others
What the payments were for
- Consulting fees$15,05863%
- Speaking & faculty fees$1,8208%
- Travel & lodging$2,88312%
- Food & beverage$4,07617%
- Education$950%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 34 | $16,550 |
| Sanofi-aventis U.S. LLC | 7 | $2,034 |
| Janssen Scientific Affairs, LLC | 8 | $1,458 |
| Kadmon Pharmaceuticals LLC | 2 | $970 |
| ADC Therapeutics America, Inc. | 1 | $640 |
| Adaptive Biotechnologies Corporation | 7 | $425 |
| Johnson & Johnson | 6 | $382 |
| Astellas Pharma US Inc | 10 | $285 |
| Syndax Pharmaceuticals, Inc. | 1 | $145 |
| Rigel Pharmaceuticals, Inc. | 2 | $130 |
| G1 Therapeutics, Inc. | 1 | $121 |
| Sobi, Inc | 1 | $119 |
| Legend Biotech USA Inc. | 2 | $106 |
| Gilead | 1 | $100 |
| Karyopharm Therapeutics Inc. | 5 | $97 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $75 |
| E.r. Squibb & Sons, L.L.C. | 2 | $70 |
| Bard Peripheral Vascular, Inc. | 2 | $51 |
| Epizyme, Inc. | 1 | $28 |
| AbbVie | 1 | $26 |
| Geron Corporation | 1 | $26 |
| Merck | 1 | $22 |
| Recordati_rare_diseases_inc. | 1 | $21 |
| Pfizer | 1 | $20 |
| Genmab U.S., Inc. | 1 | $15 |
| Medtronic | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,932 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 101 | $1,446,880 |
| RezurockBelumosudil Mesylate | 45 | $909,218 |
| PromactaEltrombopag Olamine | 39 | $719,576 |
| PomalystPomalidomide | 43 | $645,696 |
| ImbruvicaIbrutinib | 16 | $260,975 |
| VenclextaVenetoclax | 20 | $227,164 |
| JaypircaPirtobrutinib | 12 | $226,349 |
| NinlaroIxazomib Citrate | 13 | $155,344 |
| EliquisApixaban | 17 | $17,160 |
| Voriconazole | 42 | $9,931 |
| Cyclosporine | 12 | $4,369 |
| Tacrolimus | 63 | $3,406 |
| Famciclovir | 30 | $2,643 |
| ValacyclovirValacyclovir Hcl | 40 | $2,579 |
| Ursodiol | 37 | $2,432 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $16,550 | $1,446,880101 claims |
| Sanofi-aventis U.S. LLCRezurock | $2,034 | $909,21845 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $70 | $645,69643 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $75 | $260,97516 claims |
| AbbVieVenclexta | $26 | $227,16420 claims |
| PfizerEliquis | $20 | $17,16017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.
Other physician assistant in Dallas
- Cynthia TrickettDallas$1.3M
- Michael WhiteDallas$276K
- Sofia NeicherilDallas$62K
- Shawn SommerladDallas$53K
- Katherine TurnerDallas$43K
- Tori BurnsDallas$39K
- Suzanne RaczDallas$32K
- Kristine KuceraMelissa$797K
- Selina SantosAustin$543K
- Matthew BrunoMcKinney$538K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.